Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Hehlmann

Showing results (291-300 of 310) with videos related to

Pageof 31
Sort By:
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Annals of Hematology|May 6, 2004
Subgroup specific therapy effects in AML: AMLCG dataTh Büchner, W Hiddemann, W E Berdel, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Blood|November 8, 2001
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic respondersF Bonifazi, A de Vivo, G Rosti, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|March 12, 2016
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemiaT Büchner, U O Krug, R Peter Gale, et al.
Pageof 31

Showing results (291-300 of 310) with videos related to

Sort By:
Pageof 31
Leukemia|August 26, 2014
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)G Barosi, A Tefferi, C Besses, et al.
Annals of Hematology|May 6, 2004
Subgroup specific therapy effects in AML: AMLCG dataTh Büchner, W Hiddemann, W E Berdel, et al.
Leukemia|February 14, 2015
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IVL Kalmanti, S Saussele, M Lauseker, et al.
Blood|November 8, 2001
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic respondersF Bonifazi, A de Vivo, G Rosti, et al.
Leukemia|May 7, 2014
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinibB Hanfstein, V Shlyakhto, M Lauseker, et al.
Leukemia|March 23, 2007
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphomaG Metzgeroth, C Walz, J Score, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|October 3, 2003
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-CM C Müller, N Gattermann, T Lahaye, et al.
Leukemia|January 31, 2018
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Leukemia|March 12, 2016
Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemiaT Büchner, U O Krug, R Peter Gale, et al.
Pageof 31